NCT04092491Completed
Study of the IgA Repertoire During IgA Deposition Nephropathy.
Source: ClinicalTrials.gov · Last updated 24 Jun 2026
Brief summary (registry, in English)
IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective inflammatory response or, on the contrary, anti-inflammatory and inducing tolerance. Similarly, and for reasons that remain very poorly understood, they can be involved in pathologies where the immune system is itself an aggressor of the body and responsible for immunopathological lesions. The investigator formulates the hypothesis that an inappropriate response of the mucosal immune system to one or more antigens leads to a synthesis of IgA of bad affinity favoring a deposit at the level of the mesangium. It seems important to verify this point by analyzing the IgA repertory of patients with N-IgA and comparing it to that of a control population.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 80 (actual)
- First submitted
- 8 Aug 2019
- Start date
- 15 Nov 2019
- Primary completion date
- 26 Nov 2025
- Lead sponsor
- University Hospital, Limoges
- Diseases
- IgA nephropathy
- NCT number
- NCT04092491
What you commit to
- Study type: Observational
- Participants enrolled: 80
- From 15 Nov 2019 to the primary completion date, 26 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- treatment with corticosteroids or immunosuppressants for less than 12 months.
Other illness
- Secondary or associated N-IgA (infection, malignant disease, inflammatory bowel disease,
- Rheumatic autoimmune disease or other;
Other
- person on dialysis
Who the study is looking for
- Control population:
- person between the ages of 18 and 55 (persons matched to age and sex (75% male) (N-IgA is more common in humans) free from any pathology.
- oAbsence of proteinuria and hematuria on urine sample (search by strip).
- Patients with N-IgA
- 40 patients with N-IgA whose diagnosis was confirmed by renal biopsy. These may be previously known patients who have not received treatment with corticosteroids or immunosuppressants for 12 months or new patients. The incidence of N-IgA is 20 patients per Mh; the number of incident patients with N-IgA is 10-15 per year in the nephrology department. The recruitment of 40 patients over 1 year is feasible.
- Participant's written consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service de Néphrologie Coordinator of this site? Confirm its status | Limoges | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.